This is a paid press release. Contact the press release distributor directly with any enquiries.
New study finds GLP-1 receptor agonists associated with lower risk of alcohol-related hospitalization among adults with alcohol use disorder
Truveta
Wed, 22 July 2026 at 4:15 am GMT+5:30
4 min read
Large multi-system study using target trial emulation found consistent associations across patients with alcohol use disorder and either type 2 diabetes or obesity
BELLEVUE, Wash., July 21, 2026 (GLOBE NEWSWIRE) — Researchers from Truveta, Johns Hopkins Bloomberg School of Public Health, Duke University, Providence, and collaborating institutions have published a new study finding that adults with alcohol use disorder (AUD) who initiated newer glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, experienced lower rates of alcohol-related hospitalization compared with patients receiving alternative treatments for diabetes or obesity.
Published in BMJ Open, the study, Association between GLP-1 receptor agonists and alcohol-related hospitalizations among adults with alcohol use disorder: A multi-target trial emulation study, analyzed electronic health record data from more than 40,000 adults with AUD and either type 2 diabetes or obesity across US health systems
Using a target trial emulation framework designed to emulate randomized clinical trials in real-world data, researchers conducted four separate analyses representing distinct clinical populations and treatment contexts. Across these populations, initiation of semaglutide or tirzepatide was consistently associated with a lower observed risk of alcohol-related emergency department visits and hospitalizations
Among adults with AUD and type 2 diabetes, initiation of a newer GLP-1 RA was associated with a 22%–26% lower hazard of alcohol-related hospitalization compared with other commonly prescribed diabetes medications. Among adults with AUD and obesity, newer GLP-1 RAs were associated with a 32% lower hazard of alcohol-related hospitalization compared with other anti-obesity medications. In analyses comparing GLP-1 RAs with medications approved for alcohol use disorder, researchers also observed substantially lower rates of alcohol-related hospitalization among GLP-1 RA users, though those findings should be interpreted more cautiously because the groups may have differed in ways that are difficult to fully account for by statistical approaches.
“Alcohol use disorder remains one of the most common and undertreated chronic conditions in the United States,” said Hemalkumar B. Mehta, PhD, MS, Johns Hopkins Bloomberg School of Public Health Department of Epidemiology and corresponding author. “Our findings add to a growing body of evidence suggesting that GLP-1 receptor agonists may influence alcohol-related outcomes, while also highlighting the need for randomized clinical trials to determine whether these medications have a causal role in reducing alcohol-related harm.”
